SNP614 / SciNeuro Pharma - LARVOL DELTA

SciNeuro has received funding of $5M from The Michael J. Fox Foundation for Parkinson's Research, as part of MJFF's Therapeutics Pipeline Program, to accelerate the preclinical development of the company's novel, next generation anti-sense oligonucleotide program (SNP614) targeting LRRK2. (PRNewswire)

Financing • Parkinson's Disease

Nonhuman primate efficacy and safety of snp614, a lrrk2 antisense oligonucleotide as potential therapeutic agent for parkinson's disease (MDS Congress 2024) - "SNP614 has exhibited broad distribution and long-lasting knock-down effect including significant LRRK2 reduction in deep brain regions critical for achieving PD treatments. It exhibits excellent target engagement (TE), in vitro/in vivo (IVIV), and pharmacokinetic/pharmacodynamic (PK/PD) correlation, as well as long-lasting and exposure dependent efficacy and safety. We report the discovery of SNP614, the lead development candidate, that reduces LRRK2 mRNA levels to broadly lower PD-associated LRRK2 overactivation in NHP CNS."

Clinical • Late-breaking abstract • CNS Disorders • Parkinson's Disease • LRRK2

SciNeuro Pharmaceuticals to Present Preclinical Efficacy and Safety Data on SNP614, a Novel Antisense Oligonucleotide Directed to LRRK2, at the 2024 International Congress of Parkinson's Disease and Movement Disorders (PRNewswire) - "SciNeuro Pharmaceuticals...today announced that it will present its next generation antisense oligonucleotide (ASO) therapeutic candidate SNP614 at the International Congress of Parkinson's Disease and Movement Disorders, in Philadelphia, PA, USA from September 27 – October 1, 2024. The lead candidate, SNP614, which targets leucine-rich repeat kinase 2 (LRRK2) for treatment of Parkinson's Disease (PD), has demonstrated potent in vivo activity, with substantial decreases in LRRK2 mRNA levels observed in CNS regions of therapeutic interest. The data to be presented, including in vivo efficacy data from non-human primate studies, further supports the therapeutic potential of SNP614 as a novel, next generation ASO in the treatment of Parkinson's Disease."

Preclinical • CNS Disorders • Parkinson's Disease

IN VIVO EFFICACY AND TOLERABILITY OF SNP614, A LRRK2 ANTISENSE OLIGONUCLEOTIDE AS POTENTIAL THERAPEUTIC AGENT FOR PARKINSON'S DISEASE (ADPD 2024) - "We report the discovery of ASOs that reduce LRRK2 mRNA levels to broadly lower PD-associated LRRK2 overactivation in CNS. These ASOs are potent, efficacious, and well-tolerated, and have excellent potentials to be developed as therapeutic agents for PD."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease • LRRK2 • RAB10